Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

GYGo YamamotoKKKosei Kageyama

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals CAR T-cell therapy improves progression-free survival in R/R large B-cell lymphoma, suggesting effective risk stratification using key prognostic factors.

Key Points

  • This analysis aims to identify prognostic determinants and develop a score to stratify progression risk in patients receiving CAR T-cell therapy.
  • Conducted a retrospective analysis of 93 patients with relapsed/refractory large B-cell lymphoma
  • Evaluated pre-treatment clinical and laboratory variables for prognostic significance
  • Assessed efficacy using Lugano 2014 criteria and graded toxicities as per ASTCT consensus criteria
  • Identified prognostic factors using univariate and multivariate Cox proportional hazards models.
  • Overall response rate was 66.7% with a complete response of 51.6%.
  • Median follow-up was 6.7 months with median progression-free survival not reached.
  • Sensitivity to bridging therapy was the strongest predictor of favorable outcomes.
  • Developed the Toranomon Prognostic Score based on three key pre-treatment factors.

Cite This Study

Yamamoto et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d588https://doi.org/10.1182/blood-2025-1942
View Full Paper
Ask AI
Bookmark
Share